Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results?

• Voyager Therapeutics, Inc. recently reported fourth-quarter 2025 results showing a net loss of US$27.43 million, improving from US$34.49 million a year earlier, while its full-year 2025 net loss widened to US$119.72 million from US$65.00 million in 2024.
• Although Voyager reduced its quarterly loss per share, the much larger full-year loss highlights the cost intensity of advancing its neurological disease pipeline.
• We’ll now examine how Voyager’s improved quarterly loss but much larger full-year deficit could influence the company’s longer-term investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Voyager Therapeutics Investment Narrative Recap

To own Voyager Therapeutics, you need to be comfortable backing a high-cost, high-risk neurology pipeline while the company remains unprofitable. The latest results show a smaller Q4 loss but a sharply larger full-year deficit, which highlights ongoing cash burn. This does not materially change the near term focus on advancing key tau and gene therapy programs, but it keeps financing and partnership risk front and center for the story right now.

Against this backdrop, the February 2026 resignation of Chief Medical Officer Toby Ferguson is particularly relevant. Voyager’s programs depend heavily on disciplined clinical execution, so investors may watch closely how CEO Alfred Sandrock’s interim oversight of clinical development aligns with upcoming trial milestones. Any shift in how efficiently Voyager converts R&D spend into clinical progress could influence confidence in both its catalysts and its ability to manage continued losses.

But alongside those opportunities, one underappreciated risk investors should be aware of is how Voyager’s dependence on external partnerships could...

Read the full narrative on Voyager Therapeutics (it's free!)

Voyager Therapeutics’ narrative projects $92.0 million revenue and $13.0 million earnings by 2028.

Uncover how Voyager Therapeutics' forecasts yield a $15.67 fair value, a 222% upside to its current price.

Exploring Other Perspectives

You might find it useful to compare this with the more optimistic analysts who, before this update, were assuming revenue could reach about US$138.3 million with earnings of around US$19.6 million in a few years. That view leans heavily on successful milestones and partnerships, so the latest US$119.72 million annual loss and leadership changes could lead them to revisit how realistic those assumptions look.

Explore 5 other fair value estimates on Voyager Therapeutics - why the stock might be worth just $8.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Voyager Therapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
• Our free Voyager Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Voyager Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com